Bachem Holding AG
SIX:BANB
Bachem Holding AG
Operating Income
Bachem Holding AG
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bachem Holding AG
SIX:BANB
|
Operating Income
CHf133m
|
CAGR 3-Years
1%
|
CAGR 5-Years
16%
|
CAGR 10-Years
14%
|
|
|
Siegfried Holding AG
SIX:SFZN
|
Operating Income
CHf199.3m
|
CAGR 3-Years
13%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Lonza Group AG
SIX:LONN
|
Operating Income
CHf1.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
Tecan Group AG
SIX:TECN
|
Operating Income
CHf70.3m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
PolyPeptide Group AG
SIX:PPGN
|
Operating Income
-€5.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SKAN Group AG
SIX:SKAN
|
Operating Income
CHf37.8m
|
CAGR 3-Years
52%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
Bachem Holding AG
Glance View
In the heart of the Swiss pharmaceutical industry, Bachem Holding AG has carved out a distinct niche as a leading player in the peptide manufacturing landscape. Founded by Peter Grogg in 1971, Bachem has grown from a modest laboratory venture into a global powerhouse with an exceptional focus on peptides and oligonucleotide development. These biomolecules, small chains of amino acids, and nucleotides respectively, play crucial roles in modern therapeutics, acting as key components in drug design for treating various ailments. From its headquarters in Bubendorf, Switzerland, Bachem leverages cutting-edge technologies to enhance the purity and scalability of peptide production, meeting the demand from pharmaceutical and biotechnology companies worldwide. By establishing a robust supply chain and maintaining high standards of quality control, the company ensures the reliability and success of its partnerships. At the core of Bachem's business model is the offering of customized products and services tailored to client-specific needs, ranging from research-grade to commercial-scale production. The company generates revenue through long-term contracts and ongoing relationships with key players in the global pharmaceutical industry. As drug discovery advances, Bachem’s role in providing essential active pharmaceutical ingredients (APIs) becomes increasingly central, facilitating the development of novel therapies. The company also invests heavily in research and development to continuously refine its manufacturing processes and expand its service portfolio. By marrying scientific expertise with strategic foresight, Bachem not only anchors itself in the present pharmaceutical landscape but also positions itself for future growth in the biotechnology sector.
See Also
What is Bachem Holding AG's Operating Income?
Operating Income
133m
CHF
Based on the financial report for Dec 31, 2024, Bachem Holding AG's Operating Income amounts to 133m CHF.
What is Bachem Holding AG's Operating Income growth rate?
Operating Income CAGR 10Y
14%
Over the last year, the Operating Income growth was 3%. The average annual Operating Income growth rates for Bachem Holding AG have been 1% over the past three years , 16% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet